Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2750
Single User License Price INR 196323
Corporate User License Price USD 4500
Corporate User License Price INR 321255
Site License Price USD 3500
Site License Price INR 249865
Request a Quote

Report Title

Liquid Biopsy Market - Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Quote Request for License Type
License Type Price  
Single User License USD 2750
Site License USD 3500
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Liquid Biopsy Market - Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023


Quote Request for License Type
License Type Price  
Single User License USD 2750
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Liquid Biopsy Market - Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Liquid Biopsy Market - Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023



Executive Summary

Liquid Biopsy Market-Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Overview: Liquid biopsy is a minimally or non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. These tests have considerable potential for early detection of cancer, treatment and recurrence monitoring, detection of genetic abnormalities in fetus, and graft rejection in transplantation patients. According to the estimation of National Cancer Institute, in the US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths are estimated in 2016. While in Europe 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.

The liquid biopsy market is booming due to the rising prevalence of cancer globally, advanced maternal age leading to growing chromosomal aberrations, and the increasing preference of non-invasive liquid biopsy tests over invasive tissue biopsy. The lack of sensitivity and specificity of liquid biopsy tests, high cost of the test with fewer reimbursement facilities, and the lack of trained professionals are some of the factors hampering the market growth. The markets in emerging countries are expected to grow at a rapid pace during the forecast period due to the increasing disease prevalence, healthcare awareness, and healthcare spending.

Market Analysis: The Global Liquid Biopsy Market is estimated to witness a CAGR of 24.1% during the forecast period 2017-2023. The market is analyzed based on three segments, namely biomarker type, sample type, application, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the liquid biopsy market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.

Biomarker Type Analysis: The global liquid biopsy market by biomarker type is segmented into circulating tumor cell (CTC), cell-free DNA (cfDNA), extracellular vesicles, and others. Cell-free DNA (cfDNA) segment is the largest segment in 2016 due to its wide range of application in prenatal testing, transplantation diagnostics, and oncology.

Sample Type Analysis: The global liquid biopsy market by sample type is segmented into blood and others. Blood sample occupies the major market share in 2016 since most of the tests currently available in the market are blood-based tests.

Application Analysis: The global liquid biopsy market by application is segmented into cancer and non-cancer applications. Cancer segment occupies the largest market share and is expected to be the fastest growing segment during the forecasted period. Cancer application is further segmented by cancer indication and clinical application.

End-users Analysis: The global liquid biopsy market by end-users is segmented into hospital and reference laboratories, academic and research institutes, and others. Hospital and reference laboratories occupied a major share of liquid biopsy market in 2016 due to the increasing volume of test samples outsourced to this segment.

Key Players: Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.

Competitive Analysis: Currently, cancer tests dominate the global liquid biopsy market. A lot of new players are concentrating on this market to provide ground-breaking test with high sensitivity, specificity, and less turnaround time. Major market players are acquiring small companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, the major players are launching innovative tests to have an upper hand in the market. For instance, in September 2017, Biocept launched Liquid Biopsy test for NRAS mutations.

Benefits: The report provides complete details about the usage and adoption rate of liquid biopsy tests in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding their business in this market.

Key Stakeholders:

Table of Contents

1 INDUSTRY OUTLOOK 9

1.1 Industry overview 9

1.2 Total addressable market 9

1.3 Industry Trends 10

2 Report Outline 11

2.1 Report Scope 11

2.2 Report Summary 11

2.3 Research Methodology 12

2.4 Report Assumptions 12

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Importance of Cell-Free DNA testing 13

3.3 Complications of Cell-Free DNA testing 13

3.4 Segmented Addressable Market (SAM) 14

3.5 Industry Trends 14

3.6 Related Markets 16

3.6.1 Liquid biopsy market 16

3.6.2 Transplantation Diagnostics Market 16

4 Market Outlook 16

4.1 Overview 16

4.2 Regulatory framework 17

4.3 Funding scenario 18

4.4 Market segmentation 19

4.5 PEST Analysis 20

4.6 Porter 5(Five) Forces 21

5 Market Characteristics 22

5.1 DRO-Global Cell-free DNA testing Market Dynamics 22

5.1.1 Drivers 22

5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies 22

5.1.1.2 Rising number of cancers 23

5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis 23

5.1.2 Opportunities 24

5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries 24

5.1.2.2 Increase in mergers & acquisitions 24

5.1.3 Restraints 24

5.1.3.1 High test cost with less reimbursement facilities 24

5.1.3.2 Ethical issues 25

5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing 25

6 Test Types: Market Size and Analysis 28

6.1 Overview 28

6.2 Non-invasive prenatal tests (NIPT) 29

6.3 Circulating tumour DNA tests 30

6.4 Donor-derived cell free DNA tests 32

7 Application: Market Size and Analysis 33

7.1 Overview 33

7.2 Prenatal testing 35

7.3 Cancer 35

7.4 Transplantation diagnostics 36

8 Regions: Market Size and Analysis 37

8.1 Overview 37

8.2 North America 38

8.2.1 Overview 38

8.2.2 United states 38

8.2.3 Canada 39

8.3 Europe 39

8.3.1 Overview 39

8.3.2 United Kingdom 40

8.3.3 Germany 41

8.3.4 France 41

8.3.5 Spain 41

8.4 APAC 42

8.4.1 Overview 42

8.4.2 India 42

8.4.3 China 43

8.5 Rest of the World 43

8.5.1 Overview 43

8.5.2 Brazil 44

8.5.3 Middle East 44

9 Competitive Landscape 45

9.1 Overview 45

10 Vendor Profiles 48

10.1 Natera, Inc. 48

10.1.1 Overview 48

10.1.2 Natera Inc.: Product offerings 48

10.1.3 NATERA, INC.: Recent Developments 49

10.1.4 Geographic Presence 52

10.1.5 Business Focus 52

10.1.6 SWOT Analysis 53

10.1.7 Business Strategy 53

10.2 Laboratory Corporation of America Holdings (LABCORP) 54

10.2.1 Overview 54

10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings 55

10.2.3 Laboratory Corporation Of America Holdings: Recent Developments 56

10.2.4 Business Unit 58

10.2.5 Geographic Presence 58

10.2.6 Business Focus 59

10.2.7 SWOT Analysis 59

10.2.8 Business Strategy 60

10.3 Illumina, Inc., 61

10.3.1 Overview 61

10.3.2 Illumina, INC: Product offerings 61

10.3.3 Illumina, INC: Recent Developments 62

10.3.4 Geographic Presence 66

10.3.5 Business Focus 66

10.3.6 SWOT Analysis 67

10.3.7 Business Strategy 67

10.4 BEIJING GENOMICS INSTITUTE 68

10.4.1 Overview 68

10.4.2 Beijing Genomics Institute: Product offerings 68

10.4.3 Beijing Genomics Institute: Recent Developments 69

10.4.4 Business Focus 69

10.4.5 SWOT Analysis 69

10.4.6 Business Strategy 70

10.5 F.Hoffmann-La Roche Ltd 71

10.5.1 Overview 71

10.5.2 F. Hoffmann-la Roche: Product Offerings 71

10.5.3 F. Hoffmann-la roche.: Recent Developments 72

10.5.4 Business Unit 75

10.5.5 Geographic Presence 76

10.5.6 Business Focus 76

10.5.7 SWOT Analysis 77

10.5.8 Business Strategy 77

Companies to Watch For 78

10.6 CareDx, Inc 78

10.6.1 Overview 78

10.6.2 caredx: Recent Developments 79

10.7 LifeCodexx AG 80

10.7.1 Overview 80

10.7.2 LifeCodexx AG: Recent Developments 80

10.8 Biocept, Inc. 81

10.8.1 Overview 81

10.8.2 Biocept, Inc.: Recent Developments 82

10.9 Quest Diagnostics 84

10.9.1 Overview 84

10.9.2 Quest Diagnostics: Recent Developments 85

10.10 Guardant Health 87

10.10.1 Overview 87

10.10.2 Guardant Health: Recent Developments 87

10.11 Inivata Limited 89

10.11.1 Overview 89

10.11.2 Inivata Limited: Recent Developments 89

10.12 Personal Genome Diagnostics 90

10.12.1 Overview 90

10.12.2 Personal Genome Diagnostics: Recent Developments 91

10.13 Trovagene 91

10.13.1 Overview 91

10.13.2 Trovagene, Inc.: Recent Developments 92

Annexure 94

Abbreviations 94

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL CELL-FREE DNA TESTING MARKET 12

CHART 2 WORLDWIDE CELL-FREE DNA TESTING MARKET REVENUE, 2016-2023 (USD MILLION) 15

CHART 3 PEST ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET 20

CHART 4 PORTER 5 FORCES ON GLOBAL CELL-FREE DNA TESTING MARKET 21

CHART 5 DRO-IMPACT ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET 27

CHART 6 KEY STAKEHOLDERS 27

CHART 7 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2016 (%) 29

CHART 8 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2023 (%) 30

CHART 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE FORECAST,

2016-2023 (USD MILLION) 31

CHART 10 GLOBAL CIRCULATING TUMOUR DNA MARKET REVENUE FORECAST, 2016-2023 (USD MILLION) 32

CHART 11 GLOBAL DONOR-DERIVED CELL-FREE DNA TESTING MARKET REVENUE FORECAST, 2016-2023 (USD MILLION) 33

CHART 12 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION SEGMENTATION, 2016 (%) 35

CHART 13 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION SEGMENTATION, 2023 (%) 35

CHART 14 GLOBAL CELL-FREE DNA TESTING MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 (%) 38

CHART 15 CELL-FREE DNA TESTING MARKET REVENUE IN NORTH AMERICA, 2016-2023 (USD MILLION) 39

CHART 16 CELL-FREE DNA TESTING MARKET REVENUE IN EUROPE, 2016-2023 (USD MILLION) 41

CHART 17 CELL-FREE DNA TESTING MARKET REVENUE IN ASIA-PACIFIC, 2016-2023 (USD MILLION) 43

CHART 18 CELL-FREE DNA TESTING MARKET REVENUE IN REST OF THE WORLD, 2016-2023 (USD MILLION) 44

CHART 19 NATERA: OVERVIEW SNAPSHOT 52

CHART 20 NATERA: GEOGRAPHIC PRESENCE 53

CHART 21 NATERA: SWOT ANALYSIS 54

CHART 22 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT 58

CHART 23 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS 59

CHART 24 LABORATORY CORPORTATION OF AMERICA HOLDINGS: GEOGRAPHICAL PRESENCE 59

CHART 25 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 60

CHART 26 ILLUMINA, INC: OVERVIEW SNAPSHOT 65

CHART 27 ILLUMINA, INC: GEOGRAPHIC PRESENCE 67

CHART 28 ILLUMINA, INC: SWOT ANALYSIS 68

CHART 29 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS 70

CHART 30 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT 75

CHART 31 F. HOFFMANN.LA ROCHE: BUSINESS UNITS 75

CHART 32 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 77

CHART 33 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS 78

Tables

TABLE 1 FUNDING SCENARIO 18

TABLE 2 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPES, 2016-2023 (USD MILLION) 30

TABLE 3 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION, 2016-2023 (USD MILLION) 34

TABLE 4 GLOBAL CELL-FREE DNA TESTING MARKET REVENUE BY REGIONS, 2016-2023 (USD MILLION) 38

TABLE 5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET BY VENDOR RANKING, 2016 47

TABLE 6 OTHER PROMINENT VENDORS OF CELL-FREE DNA TESTING MARKET 48

TABLE 7 CAREDX, INC.: SNAPSHOT 79

TABLE 8 LIFECODEXX AG.: SNAPSHOT 81

TABLE 9 BIOCEPT, INC.: SNAPSHOT 83

TABLE 10 QUEST DIAGNOSTICS: SNAPSHOT 85

TABLE 11 GUARDANT HEALTH INC.: SNAPSHOT 88

TABLE 12 INIVATA LIMITED: SNAPSHOT 90

TABLE 13 PERSONAL GENOME DIAGNOSTICS: SNAPSHOT 91

TABLE 14 TROVAGENE, INC.: SNAPSHOT 93

Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person